Stock Ratios
Making an investment decision in the stock market involves a certain amount of risk, so it's important to thoroughly review a company's stock before making any decisions. Stock float, number of short positions and outstanding shares are among the many factors an investor should take into account.
profit margin TTM
-22215.39%
operating margin TTM
-25384.68%
revenue TTM
445.67 Million
revenue per share TTM
4.64$
valuation ratios | |
|---|---|
| pe ratio | -8.67 |
| peg ratio | 0.52 |
| price to book ratio | 2.62 |
| price to sales ratio | 2,055.18 |
| enterprise value multiple | -8.63 |
| price fair value | 2.62 |
profitability ratios | |
|---|---|
| gross profit margin | -8560.01% |
| operating profit margin | -25384.68% |
| pretax profit margin | -22076.59% |
| net profit margin | -22215.39% |
| return on assets | -25.67% |
| return on equity | -31.53% |
| return on capital employed | -31.41% |
liquidity ratios | |
|---|---|
| current ratio | 13.25 |
| quick ratio | 13.25 |
| cash ratio | 2.38 |
efficiency ratios | |
|---|---|
| days of inventory outstanding | 0.00 |
| operating cycle | 0.00 |
| days of payables outstanding | 17.93 |
| cash conversion cycle | -17.93 |
| receivables turnover | 0.00 |
| payables turnover | 20.36 |
| inventory turnover | 0.00 |
debt and solvency ratios | |
|---|---|
| debt ratio | 0.17 |
| debt equity ratio | 0.21 |
| long term debt to capitalization | 0.09 |
| total debt to capitalization | 0.17 |
| interest coverage | 0.00 |
| cash flow to debt ratio | -0.87 |
cash flow ratios | |
|---|---|
| free cash flow per share | -3.85 |
| cash per share | 22.06 |
| operating cash flow per share | -3.84 |
| free cash flow operating cash flow ratio | 1.00 |
| cash flow coverage ratios | -0.87 |
| short term coverage ratios | -18.57 |
| capital expenditure coverage ratio | -377.48 |
Frequently Asked Questions
When was the last time CRISPR Therapeutics AG (NASDAQ:CRSP) reported earnings?
CRISPR Therapeutics AG (CRSP) published its most recent earnings results on 10-11-2025.
What is CRISPR Therapeutics AG's current ROE?
An investor's main concern is the profitability ratios of a company so that they are able to understand how it performs financially. Investors are interested in finding out how effectively a business is using their cash to produce earnings, which is why return on equity (ROE) ratio is important. CRISPR Therapeutics AG (NASDAQ:CRSP)'s trailing twelve months ROE is -31.53%.
What are ROA telling us?
The Return on Assets (ROA) ratio measures how profitable a company is relative to its total assets. CRISPR Therapeutics AG (CRSP) currently has a ROA of -25.67%. Companies that manage their assets effectively will have greater returns, while those that do so poorly would suffer lower returns.
Where did CRSP's net profit margin stand at?
CRSP reported a profit margin of -22215.39% in the last quarter. A company's profit margin, also known as its revenue ratio or gross profit ratio, reflects the amount of revenue that an organization earns compared to its net income. In general, a higher ratio implies greater profit, and vice versa.
What is CRSP's short-term liquidity position?
Apple's current ratio, which measures its ability to pay short-term obligations, was 13.25 in the most recent quarter. The quick ratio stood at 13.25, with a Debt/Eq ratio of 0.21.